Elsevier

Vaccine

Volume 12, Issue 9, 1994, Pages 771-772
Vaccine

Short paper
Influence of smoking on immunological responses to hepatitis B vaccine

https://doi.org/10.1016/0264-410X(94)90283-6Get rights and content

Abstract

When 115 health-care workers participated in a study that monitored their serological responses to hepatitis B vaccine at regular intervals, it was found that smoking significantly affected their antibody titre responses adversely. The study group was randomly allocated into two comparable groups that received hepatitis B vaccine either in a rapid schedule (vaccination at 0, 1, 2 and 12 months) or a standard schedule — most commonly used worldwide — (vaccination at 0, 1, and 6 months). A significantly higher proportion of smokers, in both schedules, failed to seroconvert and to achieve higher antibody levels at month 3 (p=0.01) and at month 13 (p=0.0003). At month 7 a similar pattern was noted in smokers following the standard vaccination schedule (p⩽0.05), but not in those following the rapid schedule.

References (5)

There are more references available in the full text version of this article.

Cited by (86)

  • Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research

    2022, The Lancet Respiratory Medicine
    Citation Excerpt :

    However, results from a randomized, double-blind, placebo-controlled trial on the efficacy of influenza vaccination189 found a greater antibody titre rise due to vaccination in smokers compared with non-smokers. By contrast, hepatitis B vaccination has been found to be less immunogenic in smokers versus non-smokers.190,191 A recent meta-analysis found that 17 of 23 studies of responses to SARS-CoV-2 vaccines showed much lower antibody titres or more rapid lowering of vaccine-induced IgG in smokers than in non-smokers.192

  • TLR3 and TLR7/8 agonists improve immunization outcome in nicotine exposed mice through different mechanisms

    2022, Immunology Letters
    Citation Excerpt :

    Smokers, who represent more than one billion people worldwide, are identified as a subpopulation with higher incidence and severity of infectious diseases despite getting vaccinations [3,4]. Indeed, studies report that smokers have quantitatively and/or qualitatively impaired immune responses to natural infections [5,6] and booster vaccines [7–14]. Therefore, the refinement of current vaccines and development of more efficacious future vaccines to enhance immunity across populations are needed to reduce vaccine failure rates and thus increase the herd effect of vaccines during pandemic and epidemic outbreaks.

  • Vaccination in Chronic Liver Disease: An Update

    2022, Journal of Clinical and Experimental Hepatology
    Citation Excerpt :

    Currently, both single antigen vaccines such as Engerix-B, Heplisav-B, Recombivax-HB and combination vaccines such as Twinrix (combined hepatitis A and B vaccines) are available. Although these vaccines are highly immunogenic in healthy individuals (>90%), multiple studies have shown that factors such as advanced age, male gender, obesity, diabetes mellitus, and chronic kidney disease are associated with reduced immune response.61–64 Similarly, seroconversion is poor in those with CLD, and vaccine efficacy wanes with the increasing severity of the liver disease.

  • SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study

    2022, Vaccine
    Citation Excerpt :

    The effect of smoking is discussed with patients undergoing any kind of vaccination. Studies showed a reduced effectiveness of vaccinations, for example in hepatitis vaccination, due to a general immunosuppression caused by smoking [23,24]. Additionally, studies in patients after organ transplantation have suggested that immunosuppression could led to a reduced antibody response [25].

  • Hepatitis B Vaccines

    2017, Plotkin's Vaccines
View all citing articles on Scopus
View full text